# Tislelizumab Combined With Chemotherapy and Relayed Radiotherapy in First-line Treatment of ES-SCLC

> **NCT06838208** · PHASE2 · RECRUITING · sponsor: **Anhui Provincial Cancer Hospital** · enrollment: 56 (estimated)

## Conditions studied

- Extensive-stage Small Cell Lung Cancer (ES-SCLC)

## Interventions

- **DRUG:** Tislelizumab, Carboplatin /Cisplatin, Etoposide

## Key facts

- **NCT ID:** NCT06838208
- **Lead sponsor:** Anhui Provincial Cancer Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-02-25
- **Primary completion:** 2027-03-01
- **Final completion:** 2028-04-01
- **Target enrollment:** 56 (ESTIMATED)
- **Last updated:** 2025-09-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06838208

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06838208, "Tislelizumab Combined With Chemotherapy and Relayed Radiotherapy in First-line Treatment of ES-SCLC". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT06838208. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*